FDA Approves Onapgo (apomorphine) for Motor Fluctuations in Advanced Parkinson's
The FDA has approved Onapgo (apomorphine hydrochloride) for the treatment of motor fluctuations in adults with advanced Parkinson's disease. Onapgo is a dopaminergic agonist administered as a continuous subcutaneous infusion, intended for patients who experience OFF episodes despite optimized oral therapy. The approval provides a new option for managing motor complications in advanced disease. The label does not include specific clinical trial data, but the recommended dosing and safety information are detailed. Onapgo is not substitutable for intermittent apomorphine products. Clinicians should note the requirement for premedication with trimethobenzamide to reduce nausea and vomiting, and the contraindication with 5HT3 antagonists due to risk of hypotension and loss of consciousness.
＋ Clinical Details (Mechanism · Dosing · Trial Data · Warnings)
Apomorphine is a non-ergoline dopamine agonist with high affinity for dopamine D4 receptors, and moderate affinity for dopamine D2, D3, D5, and adrenergic α1D, α2B, α2C receptors. The precise mechanism of action in Parkinson's disease is unknown, but it is thought to be due to stimulation of postsynaptic dopamine D2-type receptors within the caudate-putamen in the brain.
Onapgo is indicated for the treatment of motor fluctuations in adults with advanced Parkinson's disease.
Onapgo is for subcutaneous use by infusion only. The recommended initial continuous dosage is 1 mg/hr, with a maximum of 6 mg/hr for up to 16 hours per day. Extra doses may be used as a loading dose or for acute OFF symptoms, titrated in 0.5 mg or 1 mg increments, with subsequent extra doses between 0.5 mg and 2 mg, at least 3 hours apart, up to 3 extra doses per day. Maximum total daily dosage is 98 mg. Premedication with trimethobenzamide 300 mg three times daily is recommended starting 3 days prior to first dose, continued no longer than 2 months. For mild or moderate renal impairment, initial extra dose is 0.5 mg to 1 mg, not exceeding 1 mg.
Trial data not available in label.
Contraindicated with concomitant use of 5HT3 antagonists (e.g., ondansetron, granisetron, dolasetron, palonosetron) and alosetron due to risk of profound hypotension and loss of consciousness. Warnings include nausea and vomiting, somnolence, dizziness, and falls, especially with trimethobenzamide. Not substitutable for intermittent apomorphine products.
Onapgo provides a continuous dopaminergic stimulation option for advanced Parkinson's disease patients with motor fluctuations not adequately controlled by oral medications. It requires careful patient selection, training on the infusion device, and monitoring for adverse effects. Its role is similar to other apomorphine infusions but with a specific delivery system.
View Original Abstract ↓
Intravenous tenecteplase improves functional outcomes but increases hemorrhage risk in non-large vessel occlusion acute ischemic stroke
Tenecteplase improves stroke recovery but increases bleeding risk in late treatment window
Related in Neurology
From Other Specialties
